Autoinjector is available in a Triple Pack
Efficacy for AJOVY

More migraine-free days in patients with an inadequate response to 2 or more prior preventive treatments1*

The FOCUS study demonstrated significant reduction in average monthly migraine days compared to placebo after inadequate response to 2 or more classes of preventive treatments (primary endpoint)1

Change from baseline in average monthly migraine days during the focus phase 3b study1,2

P<0.0001 vs placebo

Improvements were seen as early as week 1 and were sustained throughout the 3-month treatment period (exploratory endpoint)1†

For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Patients who achieved ≥50% reduction in monthly average migraine days1

PERCENTAGE OF PATIENTS ACHIEVING ≥50% REDUCTION IN AVERAGE MONTHLY MIGRAINE DAYS VS PLACEBO DURING THE 12-WEEK STUDY PERIOD (SECONDARY ENDPOINT)1,2

P<0.0001 vs placebo

34% of patients achieved a ≥50% reduction of average monthly migraine days with either quarterly or monthly dosing vs 9% for placebo (P<0.0001) (secondary endpoint)1

Results in patients with an inadequate response to anticonvulsants or neurotoxins (exploratory analysis)

  • 3.8 mean reduction from baseline in monthly average migraine days for both quarterly and monthly arms vs 1.0 for placebo in patients with previous anticonvulsant use2
  • 2.7 and 3.2 mean reduction from baseline in monthly average migraine days for quarterly and monthly arms, respectively, vs 0.2 for placebo in patients who previously used neurotoxins2

For all exploratory analyses, no determination of statistical significance can be made and no conclusions should be drawn.

Patients experienced a significant reduction in the monthly average number of days using migraine-specific acute headache medication (secondary endpoint)2

  • Mean reduction of 3.7 days for quarterly dosing and 3.9 days for monthly dosing of migraine-specific acute headache medication use vs 0.6 days with placebo2

What to explore next